Holen Sie sich die Stockscreener-App
44.09
1.76%
-0.79
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
UGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN) - simplywall.st
UroGen Pharma inks licensing deal with IntraGel Therapeutics - The Pharma Letter
UroGen Pharma Enters Option and Investment Deal with IntraGel Therapeutics - Kalkine Media
UroGen (NASDAQ: URGN) officer sold $750K in stock, plans more - Stock Titan
Cancer treatment co UroGen invests $7m in Israel’s IntraGelGlobes - Globes - Israel Business News
INTRAGEL THERAPEUTICS LTD announced that it expects to receive $7 million in funding from UroGen Pharma Ltd. - marketscreener.com
UroGen Pharma secures option deal with IntraGel for cancer tech By Investing.com - Investing.com Nigeria
IntraGel secures $7M from UroGen for cancer therapy development By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates UroGen Pharma stock rating on NDA filing By Investing.com - Investing.com Canada
UroGen Signs Investment, Collaboration Agreements With IntraGel for Access to Sustained-Release Platform - marketscreener.com
URGN Looks 90.6% Overvalued on GF Value™ - GuruFocus
UroGen inks equity and option deals with IntraGel (URGN:NASDAQ) - Seeking Alpha
UroGen Pharma secures option to license IntraGel SRGel program, agrees up to $7M investment - TradingView
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline - The Manila Times
IntraGel's head and neck cancer drug study gets up to $7 million for Phase 2 - Stock Titan
UroGen gets an exclusive option on TumoCure after Phase 2 - Stock Titan
Urogen Pharma stock hits 52-week high at 49.69 USD By Investing.com - Investing.com South Africa
Urogen Pharma (NASDAQ:URGN) Reaches New 1-Year HighHere's What Happened - MarketBeat
Urogen Pharma stock hits 52-week high at 49.69 USD - Investing.com
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC - Sahm
Rice Hall James & Associates LLC Purchases Shares of 300,650 Urogen Pharma $URGN - MarketBeat
The Manufacturers Life Insurance Company Has $196,000 Stock Holdings in Urogen Pharma $URGN - MarketBeat
UroGen Pharma Submits US FDA New Drug Application for UGN-103 in Recurrent Bladder Cancer - marketscreener.com
UroGen submits FDA application for bladder cancer drug UGN-103 By Investing.com - Investing.com India
URGN Looks 84.5% Overvalued on GF Value™ - GuruFocus
UroGen submits FDA application for bladder cancer drug UGN-103 - Investing.com
Ninety-nine patients entered a bladder cancer trial—what came next? - Stock Titan
California State Teachers Retirement System Grows Stock Holdings in Urogen Pharma $URGN - MarketBeat
Is UroGen Pharma (URGN) Overvalued As Sales Growth And Patent Clarity Lift Confidence? - simplywall.st
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice - Yahoo Finance
UroGen Pharma Ltd (URGN) Competitors 2026 - GuruFocus
(URGN) Volatility Zones as Tactical Triggers - Stock Traders Daily
UroGen (URGN) Q2 2026 Earnings Call Transcript - AOL.com
UroGen Pharma (URGN): TD Bank group discloses 3.37M shares, 6.9% beneficial stake - Stock Titan
Urogen Pharma (NASDAQ:URGN) Hits New 1-Year HighTime to Buy? - MarketBeat
UroGen Pharma (URGN) Is Up 21.7% After Q2 Revenue Triples And Loss Narrows Has The Bull Case Changed? - Sahm
Urogen Pharma Ltd at TD Cowen Healthcare Conference Transcript - GuruFocus
URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
UroGen Pharma Ltd. (URGN) Options Chain - Yahoo! Finance Canada
Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright - MarketBeat
UroGen Pharma (URGN) Stock Looks Fairly Priced Despite Its 210% Run - Sahm
UroGen Pharma (URGN) Earnings Put Its Fair Value Debate Back In Focus - Yahoo Finance
Why UroGen Pharma (URGN) Is Up 22.8% After Q2 2026 Revenue Nearly Tripled And Losses Narrowed - Yahoo Finance
Urogen Pharma $URGN Shares Purchased by Hennion & Walsh Asset Management Inc. - MarketBeat
UroGen Pharma Ltd. Revenue Breakdown – MUN:UR8 - TradingView
UroGen Pharma Ltd (NASDAQ: URGN) Share Price, URGN Stock News, URGN Share Price & Updates - Kalkine
Bullish: Analysts Just Made An Incredible Upgrade To Their UroGen Pharma Ltd. (NASDAQ:URGN) Forecasts - simplywall.st
Oppenheimer Adjusts PT on UroGen Pharma to $60 From $50, Maintains Outperform Rating - Moomoo
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60 - 富途牛牛
Guggenheim raises UroGen Pharma stock price target to $58 on sales beat - Investing.com South Africa
A Quick Look at Today's Ratings for UroGen Pharma Ltd(URGN.US), With a Forecast Between $48 to $75 - 富途牛牛
URGN Maintained by Guggenheim -- Price Target Raised to $58.00 - GuruFocus
Urogen Pharma (NASDAQ:URGN) Given New $75.00 Price Target at HC Wainwright - MarketBeat
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):